-
-
-
-
-
-
-
Jones Trading Downgrades Equillium (EQ) to Hold
-
-
-
-
-
-
-
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
-
-
-
-
-
-
-
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
-
-
-
-
-
-
-
Equillium (EQ) and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
-
-
-
-
-
-
-
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
-
-
-
-
-
-
-
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
-
-
-
-
-
-
-
XCHNG Announces New OnXCHNG Partners, Gaining Meaningful Ad Inventory Traction
1,192,376 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

